Limited evidences were reported about the risk of pre-pregnancy hair dye use or irregular menstruation with abnormal birth weight during pregnancy, and their joint effects were also unknown. The aim of our study was to explore whether the pre-pregnancy exposure of hair dye and irregular menstruation were associated with the risk of abnormal birth weight.
Methods
We conducted a nested case-control study from a prospective cohort of 6203 pregnant women. Low birth weight study included 315 mother-infant pairs (105 LBW cases and 210 matched controls), and macrosomia study included 381 mother-infant pairs (127 macrosomia cases and 254 matched controls). Meanwhile, lifestyle information including hair dying custom and menstrual history were collected by face-to-face questionnaires and birth outcomes were extracted from the medical records. The logistic regressions models were used to analyze the join effect of irregular menstruation and hair dye use.
Results
Pre-pregnancy hair dye use was associated with increased risk of LBW (adjusted OR = 1.71, 95% CI: 1.01-2.92, P = 0.048). Irregular menstruation had high risk of LBW (adjusted OR = 2.79, 95% CI: 1.53-5.09, P = 0.001) and macrosomia (adjusted OR = 1.93, 95% CI: 1.09-3.44, P = 0.023). Additionally, in the LBW study, women who used hair dye with pre-pregnancy BMI < 18.5 kg/m(2) had higher OR than those with only one risk factor (3.07 vs 2.53, P (trend) = 0.015), and women with both hair dye use and irregular menstruation also had higher risk than those with only one factor (4.53 vs 2.07, P (trend) = 0.05). Moreover, in macrosomia study, women with irregular menstruation and pre-pregnancy BMI ≥ 24 kg/m(2) had higher risk than those with one factor (13.31 vs 2.09, P (trend) = 0.001).
Conclusion
Our study showed that either pre-pregnancy hair dye use or irregular menstruation was associated with abnormal birth weight, especially, their joint effects could furthermore increase the risk of low birth weight infants when these two factors existed simultaneously.
Jiang Hou Huang pre-pregnancy hair dye exposure infant birth weight nested case-control, hair dye chemical exposure low birth weight macrosomia irregular menstruation interaction, pre-pregnancy environmental exposure hair color cosmetic chemicals fetal growth, BMC Pregnancy Childbirth 2018 hair dye birth weight case-control Chinese cohort, irregular menstruation hair dye joint effect abnormal birth weight risk, aromatic amines p-phenylenediamine hair dye endocrine disruption pregnancy outcome, pre-conception chemical exposure birth weight odds ratio adjusted confounders, small for gestational age large for gestational age hair dye reproductive toxicity, maternal occupational cosmetic chemical exposure fetal growth restriction evidence, hair dye use pregnancy outcome environmental reproductive epidemiology China
PMID 29743046 29743046 DOI 10.1186/s12884-018-1782-5 10.1186/s12884-018-1782-5
Cite this article
Jiang, C., Hou, Q., Huang, Y., Ye, J., Qin, X., Zhang, Y., Meng, W., Wang, Q., Jiang, Y., Zhang, H., Li, M., Mo, Z., & Yang, X. (2018). The effect of pre-pregnancy hair dye exposure on infant birth weight: a nested case-control study. BMC pregnancy and childbirth, 18(1), 144. https://doi.org/10.1186/s12884-018-1782-5
Jiang C, Hou Q, Huang Y, Ye J, Qin X, Zhang Y, et al. The effect of pre-pregnancy hair dye exposure on infant birth weight: a nested case-control study. BMC Pregnancy Childbirth. 2018;18(1):144. doi:10.1186/s12884-018-1782-5
Jiang, Chao, et al. "The effect of pre-pregnancy hair dye exposure on infant birth weight: a nested case-control study." BMC pregnancy and childbirth, vol. 18, no. 1, 2018, pp. 144.
Murvai VR et al., 2025·BMC pregnancy and childbirth
Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombotic events and adverse obstetric outcomes, particularly in its obstetric form (OAPS). Affecting approximately 0.5% of the population, APS is a leading contributor to recurrent pregnancy loss (RPL), preeclampsia (PE), and fetal growth restriction ((FGR). Despite advancements in understanding its pathophysiology and management, optimal treatment strategies for APS in pregnancy remain challenging and require systematic evaluation. This review synthesizes current evidence on APS mechanisms, diagnostic criteria, and therapeutic interventions, with a focus on maternal and fetal outcomes in OAPS. A comprehensive search of PubMed, was conducted to identify studies exploring APS pathogenesis, diagnostic standards, and treatment efficacy in obstetric settings. Inclusion criteria prioritized randomized controlled trials, cohort studies, and systematic reviews with a clear focus on APS and pregnancy. The review confirmed that APS current accepted pathogenesis is governed by a "two-hit" model, where antiphospholipid antibodies (aPLs) initiate endothelial damage, culminating in thrombosis and placental insufficiency. Epidemiological analysis underscores the prevalence and severity of APS in obstetric contexts, with lupus anticoagulant (LA) emerging as a significant predictor of adverse outcomes. Evidence supports the use of low-dose aspirin (LDA) and heparin to reduce miscarriage rates, while adjunctive treatments, such as hydroxychloroquine (HCQ), have shown promise in improving live birth rates and reducing preterm delivery in high-risk cases. Emerging therapies, including tumoral necrosis factor (TNF-alpha) inhibitors and nitric oxide modulators, may offer additional benefits in refractory cases. APS remains a critical determinant of adverse pregnancy outcomes, necessitating precise diagnostic criteria and tailored management approaches. This systematic review emphasizes the importance of individualized therapeutic regimens to optimize maternal and fetal health in OAPS and highlights areas for future research, particularly regarding novel pharmacological approaches. Further studies are essential to refine treatment protocols and improve clinical guidelines for managing APS in pregnancy.
Endometriosis affects approximately 10% of women of reproductive age and is associated with increased risks of infertility and miscarriage. Although the spontaneous miscarriage rate in women with endometriosis is higher than in the general population, specific risk factors and predictive markers for early pregnancy loss in this population remain poorly understood, particularly for women with smaller endometriomas who achieve natural conception. This study aimed to investigate risk factors for early spontaneous miscarriage in women with endometriosis with natural conception and evaluate the predictive value of uterine artery blood flow parameters and serum CA125 levels. This retrospective case-control study was conducted at the Fujian Maternity and Child Health Hospital and included 209 women with ovarian endometriomas smaller than 4 cm who achieved natural conception and intrauterine pregnancy between January 2022 and June 2024. Patients were divided into spontaneous miscarriage group (n = 61, 29.19%) and non-miscarriage group (n = 148, 70.81%) based on early pregnancy outcomes. All patients underwent follicular monitoring, endometrial assessment, and uterine artery blood flow evaluation starting from cycle days 9-10. All patients received uniform luteal support with dydrogesterone (20 mg daily from post-ovulation until 10 weeks of gestation). Variables analyzed included demographic characteristics, dysmenorrhea visual analog scale (VAS) scores, CA125 levels, baseline endocrine hormones, ovarian endometrioma characteristics, and uterine artery blood flow parameters including bilateral mean pulsatility index (PI), resistance index (RI), and systolic/diastolic ratio (S/D). No significant differences were observed between groups regarding age (29.08 ± 4.64 vs. 30.42 ± 5.09, P = 0.078), body mass index (23.15 ± 2.37 vs. 23.54 ± 2.80, P = 0.333), parity, or baseline endocrine parameters. The miscarriage group showed significantly higher CA125 levels (33.53 ± 11.87 vs. 25.57 ± 10.54, P < 0.001), bilateral mean S/D ratio (7.90 ± 3.26 vs. 5.56 ± 2.06, P < 0.001), bilateral mean PI (2.51 ± 0.43 vs. 2.22 ± 0.45, P < 0.001), and VAS scores (median 3.00 vs. 1.00, P < 0.001). Multivariate logistic regression analysis revealed that bilateral mean S/D ratio (OR = 1.38, 95% CI: 1.15-1.66, P < 0.001) and CA125 levels (OR = 1.08, 95% CI: 1.04-1.12, P < 0.001) were independently associated with increased risk of early spontaneous miscarriage. ROC analysis demonstrated good predictive value for S/D ratio (AUC = 0.75, cutoff = 6.49) and CA125 (AUC = 0.76, cutoff = 23.55), with improved diagnostic accuracy when combined (AUC = 0.85, sensitivity = 0.87, specificity = 0.72). Elevated serum CA125 levels and increased uterine artery S/D ratio are independently associated with increased risk of early spontaneous miscarriage in women with endometriosis with ovarian endometriomas smaller than 4 cm who conceive naturally. The combined assessment of CA125 levels and uterine artery S/D ratio during early pregnancy provides useful risk stratification for identifying high-risk patients, potentially enabling targeted interventions to improve pregnancy outcomes in these women.
Miscarriage is defined as spontaneous loss of pregnancy prior to 20 weeks gestation. With an estimated risk of 15% of clinically confirmed pregnancies ending in miscarriage, it is the most common adverse event in pregnancy. Woman's age is the primary risk factor for miscarriage, while medical conditions, including hormonal abnormalities, are also associated. Progesterone is essential for maintaining pregnancy. A short luteal phase may reflect inadequate levels of progesterone production, but it is unclear whether a short luteal phase correlates with an increase in the risk of miscarriage. Using a cohort study design, we conducted a secondary data analysis from four cohorts of couples who used a standardized protocol to track biomarkers of the female cycles. A short luteal phase was defined as less than 10 days, with < 11, < 9, and < 8 days as alternate definitions in sensitivity analyses. We included women who experienced a pregnancy with a known outcome, identified the length of the luteal phase in up to 3 cycles prior to conception and assessed the relationship with miscarriage using a modified Poisson regression analysis, adjusting for demographic characteristics, smoking, alcohol use and previous pregnancy history. In our sample of 252 women; the overall miscarriage rate was 18.7%. The adjusted incident risk ratio of miscarriage in women who had at least one short luteal phase < 10 days, compared to those who had none, was 1.01 (95% CI: 0.57, 1.80) Similar null risk was found when assessing alternative lengths of short luteal phase. Women who had short luteal phases < 10 days in all 3 cycles prior to the conception cycle had an incident risk ratio of 2.14 (95% CI: 0.7, 6.55). Our study found that a short luteal phase in the three cycles prior to conception was not associated with higher rates of miscarriage in an international cohort of women tracking their cycles, but our sample size was limited. Further research to determine if short luteal phases or luteal phase deficiency is associated with early pregnancy losses among preconception cohorts with daily tracking of cycle parameters, in addition to progesterone and human chorionic gonadotropin levels, is warranted. Additionally, future studies should include women with recurrent short luteal phases as a more likely risk factor than isolated short luteal phases.